| Document |
Document Title |
|
WO/2021/064189A2 |
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them hig...
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/043951A1 |
Drug conjugates having formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein D is covalently attached via a hydroxy group at OR1,...
|
|
WO/2021/045159A1 |
One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides: a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic ...
|
|
WO/2021/045681A1 |
The present invention relates to a nanoparticle which is characterized by a photoluminescent amorphous core formed from threonine and polyethylenimine (PEI), and wherein the surface of the core is functionalised with at least one carbohy...
|
|
WO/2021/045682A1 |
The present invention relates to a colorimetric method for detecting bacterial cells in a sample. The colorimetric method comprises: (a) contacting the sample with nanoparticles to form a mixture, wherein the nanoparticles are characteri...
|
|
WO/2021/037759A1 |
A novel compound is disclosed. Skin lightening composition comprising said compound and method of skin lightening is disclosed too. In addition, method of synthesizing said novel compound is disclosed.
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/024054A1 |
Techniques regarding enhancing antimicrobial activity of antirheumatic agents by combination therapy are provided. For example, one or more embodiments described herein can regard a chemical composition comprising a polycarbonate polymer...
|
|
WO/2021/018044A1 |
Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically inv...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/014442A1 |
The present invention provides pheromone compositions, kits, and formulations, as well as methods for their use in environmentally-friendly methods of pest control.
|
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/004498A1 |
It relates to glucopyranosyl derivative of formula (I) as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, a pharmaceutically acceptable salt, or a stereoisomer thereof, and further relates to a pharmaceutical composition cont...
|
|
WO/2020/262603A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, the drug containing, as an active ingredient, a compound having an antagonistic...
|
|
WO/2020/249117A1 |
The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can...
|
|
WO/2020/225273A1 |
Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment dis...
|
|
WO/2020/222103A1 |
The present invention relates to elastomer compositions comprising adducts between compounds of formula (I) preferably derived from natural sources such as mucic, pyromucic, glucaric, glycaric, galactaric, muconic acid and/or linear deri...
|
|
WO/2020/222010A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein R A, R B, R C and R D are as defined herein.
|
|
WO/2020/212543A1 |
The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive unit, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalm...
|
|
WO/2020/214901A1 |
Compositions and methods for protecting an organism from a pathogen are disclosed.
|
|
WO/2020/209035A1 |
A compound represented by formula (1). R1 is, for example, an alkyl having 1-15 carbon atoms; ring A1 and ring A2 are 1,4-phenylene, etc.; a is 2, etc.; b and c are 0, 1, or 2; Z1 is a single bond, etc.; P1 and P2 are polymerizable group...
|
|
WO/2020/210486A1 |
The disclosure provides processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxami
de, as well as intermediates for use in said processes.
|
|
WO/2020/187150A1 |
Disclosed are new crystal forms of dapagliflozin and a preparation method thereof. Particularly, the X-ray powder diffraction pattern of the crystal form A of dapagliflozin has characteristic diffraction peaks at the following 2θ angles...
|
|
WO/2020/184142A1 |
[Problem] To provide a compound which has high stability with respect to heat, high voltage holding ratio if used in a liquid crystal display element, and the like. [Solution] A compound which is represented by formula (1). In the formul...
|
|
WO/2020/183422A1 |
This disclosure relates to use of cashew nut shell liquid (CNSL) phenolics in the manufacture of molecules having ESIPT character, wherein said molecules are UVA and/or UVB absorbers, and further wherein said molecules are formulated as ...
|
|
WO/2020/171507A1 |
The present invention provides: novel compounds capable of producing monomethyl fumarate after administration; pharmaceutical compositions comprising same as active ingredients; and pharmaceutical uses thereof for treatment or alleviatio...
|
|
WO/2020/165882A2 |
The present invention relates to a method of producing high-purity 2-pyrone-4,6-dicarboxylic acid (PDC), and a method of producing an intermediate for same, the methods comprising the steps of: 1) producing terephthalic acid (TPA) from P...
|
|
WO/2020/151620A1 |
Disclosed are a compound as represented by formula II, and an isomer or available salt thereof. Also disclosed specifically are a manufacturing method for the compound, and the isomer or available salt thereof, and an application of the ...
|
|
WO/2020/151672A1 |
Provided are a new crystal form of dapagliflozin and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparation of a sodium-glucose cotransporter inhibitor and a ...
|
|
WO/2020/151623A1 |
The present invention pertains to the medical field and relates to a compound of formula (III), a stereoisomer or pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the compound, a ster...
|
|
WO/2020/151621A1 |
The present invention belongs to the field of medicine, and specifically relates to a compound of formula (I), an isomer or a pharmaceutical salt thereof. This present invention more specifically relates to a compound, a stereoisomer the...
|
|
WO/2020/076274A3 |
The present invention is related to unique caffeic acid phenethyl ester (CAPE) analogues, methods for preparation of said molecules, and the usage of said unique molecules in the preparation of a pharmaceutical composition that is to be ...
|
|
WO/2020/144297A1 |
The present invention concerns nanoemulsions encapsulating a prodrug and bearing a targeting ligand, said nanoemulsion being formed by a natural oil and/or a synthetic oil and an amphiphilic surfactant, the methods for preparing these na...
|
|
WO/2020/132820A1 |
Disclosed is a synthesis method for 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid. The acid takes furfuryl alcohol as a starting material and is prepared with four steps: rearrangement, addition, hydroxyl protection and oxidation.
|
|
WO/2020/129900A1 |
The purpose of the present invention is to provide a method for industrially and efficiently producing a C-arylhydroxy glycoxide derivative at low cost. The present invention provides a method for producing a C-arylhydroxy glucoxide deri...
|
|
WO/2018/231082A3 |
Disclosed are methods or processes of synthesizing building blocks and feedstocks for producing a broader range of polymers, including renewable polymers, from renewable resources such as CO2. In a process of manufacturing a renewable fe...
|
|
WO/2020/129899A1 |
In order to provide a method for the economical and efficient industrial production of C-aryl hydroxy glycoxide derivatives, the present invention provides a method for producing a C-aryl hydroxy glycoxide derivative represented by formu...
|
|
WO/2020/120528A1 |
The present invention provides the compounds having the general formula: (I) wherein R1 to R8, and X are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2020/120141A1 |
A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammato...
|
|
WO/2020/120643A1 |
The present invention is concerned with fragrance ingredients and with fragrance preparations, for imparting desirable odor notes to consumer products, in particular it is concerned with (2S,4R)-4-methyl-2-((Z)-2-methylbut-1-en-1-yl)tetr...
|
|
WO/2020/116555A1 |
The present invention addresses the problem of providing: a liquid crystal composition which contains a polymerizable compound and which is used for producing a PSA type or PSVA type liquid crystal display element, wherein the speed of p...
|
|
WO/2020/107124A1 |
The present invention provides a method of modulating leukocytes activation (e.g., adhesion and/or transmigration and/or cytokine response) and a method of modulating thrombocyte clearance comprising administering to a subject in need th...
|
|
WO/2020/105061A1 |
This invention is related to an improvement in the process of filtrate extension of a reaction where at least a set of filtrates of a set of reaction are mixed together to form for a filtrate extension thereby the reaction yields higher ...
|
|
WO/2020/089134A1 |
The invention relates to a process for preparing 2-substituted 4-methyl-tetrahydropyrans from 2-substituted 4-hydroxy-4-methyl-tetrahydropyrans as starting materials.
|
|
WO/2020/084559A1 |
The present invention is directed to glucopyranose derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the com...
|
|
WO/2020/086691A1 |
This current disclosure is directed to charge-transfer heptamethine dyes for NIR singlet oxygen generation, each such dye comprising a near-infrared (NIR) absorbing dye having heptamethine linkages orthogonally coupled to an optionally s...
|
|
WO/2020/084560A1 |
The present invention is directed to glucopyranose derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the p...
|
|
WO/2020/079052A1 |
The present invention refers to dihydropyran derivatives, and to a process of making the same. The invention further refers to perfume compositions and fragranced articles comprising them.
|
